MedPath

Pharmascience Inc

Pharmascience Inc logo
🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:1

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Not Applicable:1

Drug Approvals

2.6k

CANADA:1297
SFDA:9
PHILIPPINES:5
+1 more agencies

Drug Approvals

Ganciclovir

Approval Date
Dec 21, 2022
FDA

Busulfan

Approval Date
May 18, 2022
FDA

Bortezomib

Approval Date
May 2, 2022
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (33.3%)
Phase 1
1 (33.3%)
Phase 2
1 (33.3%)

Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome

Phase 2
Terminated
Conditions
Short Bowel Syndrome
Interventions
First Posted Date
2019-08-06
Last Posted Date
2022-07-19
Lead Sponsor
Pharmascience Inc.
Target Recruit Count
13
Registration Number
NCT04046328
Locations
🇵🇱

Solumed Centrum Medyczne, Poznań, Poland

🇵🇱

Szpital Wielospecjalistyczny im. Stanleya Dudricka, Skawina, Poland

🇵🇱

Wojewódzki Specjalistyczny Szpital im. M. Pirogowa w Łodzi, Łódź, Poland

Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee

Not Applicable
Completed
Conditions
Osteoarthritis, Knee
First Posted Date
2017-02-23
Last Posted Date
2020-04-21
Lead Sponsor
Pharmascience Inc.
Target Recruit Count
60
Registration Number
NCT03062787
Locations
🇨🇦

Site 04, Barrie, Ontario, Canada

🇨🇦

Site 03, Hamilton, Ontario, Canada

🇨🇦

Site 02, Kanata, Ontario, Canada

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.